Mondrian Investment Partners LTD raised its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 2.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 5,652,139 shares of the company’s stock after purchasing an additional 129,575 shares during the quarter. Sanofi comprises about 5.0% of Mondrian Investment Partners LTD’s investment portfolio, making the stock its 6th largest position. Mondrian Investment Partners LTD’s holdings in Sanofi were worth $233,038,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of the stock. Kendall Capital Management acquired a new stake in shares of Sanofi in the 3rd quarter valued at approximately $202,000. Evergreen Capital Management LLC increased its stake in Sanofi by 23.3% in the third quarter. Evergreen Capital Management LLC now owns 20,079 shares of the company’s stock valued at $828,000 after purchasing an additional 3,800 shares in the last quarter. Gibbs Wealth Management increased its stake in Sanofi by 15.7% in the third quarter. Gibbs Wealth Management now owns 29,885 shares of the company’s stock valued at $1,232,000 after purchasing an additional 4,052 shares in the last quarter. Root Financial Partners LLC bought a new stake in Sanofi in the third quarter valued at approximately $27,000. Finally, Cardinal Capital Management boosted its position in shares of Sanofi by 7.5% during the third quarter. Cardinal Capital Management now owns 86,444 shares of the company’s stock worth $3,564,000 after purchasing an additional 5,994 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts recently commented on SNY shares. Sanford C. Bernstein restated a “buy” rating on shares of Sanofi in a research report on Monday, August 3rd. Wall Street Zen cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. HSBC reiterated a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. Finally, Weiss Ratings raised shares of Sanofi from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $49.50.
Check Out Our Latest Report on SNY
Sanofi Price Performance
Sanofi stock opened at $41.60 on Friday. The company has a market capitalization of $100.86 billion, a price-to-earnings ratio of 21.78, a PEG ratio of 1.28 and a beta of 0.33. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. Sanofi has a 12 month low of $39.07 and a 12 month high of $52.68. The stock’s 50 day moving average is $42.43 and its 200-day moving average is $43.56.
Sanofi (NASDAQ:SNY – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The business’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the previous year, the business posted $3.24 earnings per share. Equities research analysts expect that Sanofi will post 5.00 EPS for the current year.
About Sanofi
Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.
The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.
Featured Articles
- Five stocks we like better than Sanofi
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
